Volume 22, Number 3—March 2016
Dispatch
Lyme Disease in Hispanics, United States, 2000–2013
Table 1
Characteristic | Hispanic, n = 5,473 | Non-Hispanic, n = 142,971 | RR (95% CI) | p value |
---|---|---|---|---|
Male sex† | 2,982 (54.8) | 78,417 (55.0) | 1.00 (0.97–1.02) | |
Median age, y (IQR) |
32 (15–46) |
42 (16–58) |
0.0001‡ |
|
Disease onset | ||||
Total with known date of disease onset | 3,826 (69.9) | 116,600 (82.6) | – | |
Summer months, Jun-Aug | 2,170 (56.7) | 77,548 (66.5) | 0.85 (0.83–0.88) | |
Fall months, Sep–Nov |
637 (16.7) |
16,821 (14.4) |
1.15 (1.07–1.24) |
|
Clinical features | ||||
Total with information on clinical features | 2,696 (49.3) | 90,180 (63.1) | – | |
Erythema migrans | 1,605 (59.5) | 64,660 (71.7) | 0.83 (0.80–0.86) | |
Arthritis | 854 (31.7) | 25,647 (28.4) | 1.11 (1.05–1.18) | |
Facial palsy | 391 (14.5) | 7,529 (8.4) | 1.74 (1.58–1.91) | |
Atrioventricular block | 36 (1.3) | 952 (1.1) | 1.26 (0.91–1.76) | |
Meningitis |
36 (1.3) |
1,026 (1.1) |
1.17 (0.84–1.63) |
|
Residence in high-incidence state§ | 4,937 (90.2) | 130,305 (91.1) | 0.90 (0.82–0.98) |
*Values are no. (%) unless otherwise indicated. Statistically significant differences between the comparison groups are in bold. IQR, interquartile range; LD, Lyme disease; RR, risk ratio.
†Percentage of persons with LD for whom sex is known (n = 5,442 Hispanics, n = 142,625 non-Hispanics).
‡The substantial difference in median age between the US Hispanic population (27 y) and the US non-Hispanic population (42 y) most likely accounts for the difference seen here.
§Defined as 1 of the 13 highest-incidence states that accounted for 95% of all reported confirmed cases of LD in 2010: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Vermont, Virginia, and Wisconsin.
Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.